Cough News and Research

RSS

ATS releases clinical practice guidelines on management of childhood ILD in infants

The American Thoracic Society has released new clinical practice guidelines on the classification, evaluation and management of childhood interstitial lung disease in infants.

1 Aug 2013

Phase III trial shows afatinib offers clinical benefit to patients with EGFR mutation positive NSCLC

Afatinib has a novel mode of action and data has shown that it offers a clinical benefit to patients with a specific type of lung cancer, which we are further investigating in the extensive LUX-Lung clinical trial programme.

1 Aug 2013

Saudi and UK scientists provide detailed picture of MERS coronavirus

Saudi and UK scientists provide the most detailed picture yet of the clinical and laboratory characteristics of Middle East Respiratory Syndrome (MERS) coronavirus, revealing a wide range of clinical symptoms and an extremely high death rate among patients with co-existing medical conditions.

29 Jul 2013

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Ligand Pharmaceuticals Incorporated partner GlaxoSmithKline announced that today, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for GSK's REVOLADE (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy

26 Jul 2013

FDA allows marketing of Xpert MTB/RIF Assay for treatment of TB

The U.S. Food and Drug Administration today allowed marketing of the Xpert MTB/RIF Assay, the first FDA-reviewed test that can simultaneously detect bacteria that cause tuberculosis and determine if the bacteria contain genetic markers that makes them resistant to rifampin, an important antibiotic for the treatment of TB.

26 Jul 2013

Viewpoints: Expanding abortion restrictions; Lift the ban on gay blood donors; Medicare's price schedules

What's going on in Wisconsin, North Dakota, South Dakota and Iowa ought to be a wake-up call to Minnesotans who prefer that physicians, not politicians, guide an individual's medical care. Minnesota's neighbors have moved with alarming alacrity to cripple women's access to a safe and legal medical procedure -; abortion (7/18).

20 Jul 2013

FDA approves Astellas' ASTAGRAF XL for prophylaxis of organ rejection in kidney transplant patients

Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the U.S. Food and Drug Administration has approved ASTAGRAF XLTM (tacrolimus extended-release capsules) for the prophylaxis of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil and corticosteroids, with or without basiliximab induction.

20 Jul 2013

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration approval of SIMPONI ARIATM (golimumab) for infusion for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate.

19 Jul 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Researchers distinguish viral and bacterial infections in children with fever

In children with fever but no other symptoms of illness, it is difficult to know whether a child has a viral infection that will resolve on its own or a potentially serious bacterial infection that requires antibiotics.

16 Jul 2013

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival.

11 Jul 2013

Study identifies new groups of people at risk of parasitic lung infection

A study conducted by Dr. James Diaz, Professor of Public Health and Preventive Medicine and Program Director of the Environmental/Occupational Health Sciences Program at the LSU Health Sciences Center New Orleans School of Public Health, analyzed cases of a parasitic lung infection and found new modes of transmission and associated behaviors, identifying new groups of people at risk.

11 Jul 2013

Diclegis delayed-release tablets for NVP treatment now eligible for Medicaid coverage

Duchesnay USA today announced that Diclegis (doxylamine succinate 10mg, pyridoxine hydrochloride 10mg) delayed-release tablets for the treatment of nausea and vomiting of pregnancy, more commonly known as morning sickness, is now available for coverage under the state and federal Medicaid program effective July 1st, 2013.

9 Jul 2013

Acorda Therapeutics acquires two neuropathic pain management assets from NeurogesX

Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia.

9 Jul 2013

Data shows individualized regimens can help optimize prophylaxis treatment in hemophilia patients

Baxter International Inc. today announced data featuring ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method], a leading recombinant treatment available worldwide, during the 24th Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Amsterdam, The Netherlands.

From Baxter International Inc. 5 Jul 2013

Research roundup: 'Welcome-mat' effect of Medicaid expansion; Setting up shops; California's transition to Medicaid managed care

The number of people eligible for Medicaid who remain uninsured varies from state to state, according to the authors. But the federal health law is likely to increase the rate of enrollment for this group. The potential impact of this increase in Medicaid enrollment, also known as the 'welcome-mat' effect, is unclear.

2 Jul 2013

Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

Janssen Research & Development, LLC announced today results of an open label, single-center, parallel group study showing that a type of medication called prothrombin complex concentrates can reverse the blood thinning effects of XARELTO (rivaroxaban) in healthy subjects.

2 Jul 2013

Study describes radiologic findings in H7N9 pneumonia

H7N9 pneumonia is characterized by imaging findings that differentiate it from other types of pneumonia, including rapidly progressive changes in the lungs and pulmonary connective tissues, according to the first study to describe radiologic findings in the disease. The results are published online in the journal Radiology.

2 Jul 2013

Coughs give vital clues to confirm the presence of pneumonia in children

A new method, which analyzes the sounds in a child's cough, could soon be used in poor, remote regions to diagnose childhood pneumonia reliably. According to Udantha Abeyratne from the University of Queensland in Australia and colleagues, this simple technique of recording coughs with a microphone on the patient's bedside table, has the potential to revolutionize the management of childhood pneumonia in remote regions around the world.

28 Jun 2013

Janssen receives complete response letter from FDA for XARELTO sNDA

Janssen Research & Development, LLC today announced the U.S. Food and Drug Administration has issued a complete response letter for the supplemental New Drug Application for XARELTO (rivaroxaban) to reduce the risk of stent thrombosis in patients with acute coronary syndrome.

28 Jun 2013

Cough News and Research

ATS releases clinical practice guidelines on management of childhood ILD in infants

Phase III trial shows afatinib offers clinical benefit to patients with EGFR mutation positive NSCLC

Saudi and UK scientists provide detailed picture of MERS coronavirus

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

FDA allows marketing of Xpert MTB/RIF Assay for treatment of TB

Viewpoints: Expanding abortion restrictions; Lift the ban on gay blood donors; Medicare's price schedules

FDA approves Astellas' ASTAGRAF XL for prophylaxis of organ rejection in kidney transplant patients

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Researchers distinguish viral and bacterial infections in children with fever

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Study identifies new groups of people at risk of parasitic lung infection

Diclegis delayed-release tablets for NVP treatment now eligible for Medicaid coverage

Acorda Therapeutics acquires two neuropathic pain management assets from NeurogesX

Data shows individualized regimens can help optimize prophylaxis treatment in hemophilia patients

Research roundup: 'Welcome-mat' effect of Medicaid expansion; Setting up shops; California's transition to Medicaid managed care

Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

Study describes radiologic findings in H7N9 pneumonia

Coughs give vital clues to confirm the presence of pneumonia in children

Janssen receives complete response letter from FDA for XARELTO sNDA

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News